The following video is part of our "Motley Fool Conversations" series, in which advisor Charly Travers and analyst Jason Moser discuss topics across the investing world.
Gilead Sciences is a world-class drug company that has created tremendous value for shareholders with a stock that's up five times over the past decade. The company, best known for its work in HIV drug development, is trying to branch out in another important anti-viral market, the treatment of hepatitis C. Gilead's recent clinical trial data on HCV drug GS-7977 was poorly received, sending the stock down 20%. Is now the time to buy?
Charly Travers and Jason Moser have no positions in the stocks mentioned above. The Motley Fool owns shares of Gilead Sciences. Motley Fool newsletter services recommend Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.
Which stock wins in a head-to-head match-up between the big biotech and the big pharma company?
Is Gilead Sciences, Inc. a Buy in 2018?
Focus on the future rather than the past for this big biotech.
2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better
In the short term, the biotech's success is still tied to its HIV and HCV franchises, but keep an eye on the pipeline.